Neovacs Announces Its Engagement in the Field of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Neovacs Announces Its Engagement in the Field of Immunotherapy in Cancer, Following the Recommendation of Its Scientific Advisory Board Which Met in New York on the 17th of November

PARIS and BOSTON, Dec. 1, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its engagement into the field of immuno-oncology. The decision is based on recommendations by the Company's Scientific Advisory Board, which met on November 17, 2015 in New York.

Neovacs convened its Scientific Advisory Board with the clear mission to identify novel cytokine/growth factor targets in oncology. Neovacs' proprietary technology is based on active immunotherapy, which stimulates a patients immune system to produce polyclonal antibodies, neutralizing pathogenic proteins.

As a result of their work, the Scientific Advisory Board recommended Neovacs to focus on the preclinical development of specific Kinoid's targeting:

The Neutralization of tumoral growth factors including VEGF-A in different types of cancer,  in particular colorectal cancer and ovarian cancers.

In phase I/II trial the Company's IFNα Kinoid demonstrated in lupus patients its ability to obtain :

  • A strong immune response in 100% of the patients (21/21 exposed to IFN-K)
  • A high level of neutralizing antibodies in the patients at the highest doses
  • A reduction of the IFN gene signature to the base level
  • Six patients from the trial were followed up for a median duration of 3 years by Neovacs, because they still have persisting anti IFNα antibodies. These six patients had no flares during this period.

Considering this capacity of the Kinoids to inhance a strong immune response, the scientific advisory board met under the chairmanship of Prof. Jacques BANCHEREAU , Director for Immunological Science, Jackson Laboratory for Genomic Medicine, Farmington, Conn.

The following scientists participated in this meeting:

  • Prof. Tanios Bekali-SAAB ,MD,Section Chief of Gastrointestinal Oncology, Professor of Medecine & Pharmacy, The Ohio State University Cancer Hospital, Ohio
  • Prof. Maura N. DICKLER , MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York
  • Prof. Robert S. KERBEL , PhD, Senior Scientist and Professor, Sunnybrook Research Institute, Biological Sciences Platform, and Dept. of Medical Biophysics,University of Toronto, Canada
  • Prof. Miriam MERAD , MD, PhD, Professor of Oncological Science, Medicine and Immunology Tisch Cancer Institute , Icahn School of Medicine at Mount Sinai, New York
  • Prof. Virginia PASCUAL , MD, Director, Center for Inflammatory and Autoimmune Diseases, Baylor Institute, Dallas, Texas
  • Prof. Richard T. PENSON , MD, MRCP, Associate Professor, Medecine, Harvard Medical School, Clinical Director for Medical Gynecologic Oncology, Boston, MA                                                 
  • Prof. Laurence ZITVOGEL , MD, PhD, Director of INSERM U1015, Head of Dpt. of Cancer Immunology and Immunotherapy at Institut Gustave Roussy, Villejuif, France

This program on oncology will be pursued in close cooperation with Prof. Robert S. Kerbel , and the Sunnybrook Research Institute, Toronto, Canada. The objective is to obtain proof of concept in relevant preclinical models in the course of 2016, before initiating clinical trials. These studies will be funded within actual cash on-hand.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr

NEOVACS - Corporate Communication & Investor Relations Charlene Masson +33 (0)1 53 10 93 00 Investor Relations / Financial Communications - NewCap Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-21-02-28-30 Press / U.S. Inquiries - The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 /

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 175

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 33

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 81

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 50

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 79

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Qfin Holdings Faces Securities Fraud Lawsuit Scrutiny

Updated Category News Views 23

Qfin Holdings Stumbles Under Legal Microscope Picture this—you're riding the stock market wave and then, out of nowhere, your investment gets hit by a sudden drop, leaving you scrambling for answers. That's the scenario investors in Qfin Holdings, Inc. (NASDAQ: QFIN) find themselves in after the company’s stock plunged by nearly 19%. Now, they're not just left...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 39

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 65

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 36

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 95

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading

Top 5 Most Recently Viewed Articles

Birkenstock Holding Q1 Earnings Highlights and Insights

Updated Category News Views 174

Birkenstock Holding Q1 Earnings Overview Birkenstock Holding (NYSE: BIRK) recently shared insights from its first quarter earnings report, showcasing the company’s financial performance and strategic advancements. This update reveals not only earnings results but also highlights on how the company is faring in a competitive market. Earnings Results The company's...

Continue Reading
Kinepolis Group Announces Upcoming Dividend Payment Details

Updated Category News Views 228

Kinepolis Group Dividend Announcement The Kinepolis Group NV is pleased to inform its shareholders of an upcoming dividend payout, a noteworthy event for investors looking to maximize their returns. Dividend Payment Details The company has officially announced a gross dividend of €0.55 per share. After the deduction of the standard 30% withholding tax, shareholders will...

Continue Reading
Celebrating Success: Medical Solutions Recognized in Regionals

Updated Category News Views 144

Celebrating Growth and Achievement for Medical Solutions Recognized for three consecutive years as a leader in healthcare workforce solutions Medical Solutions, a prominent name in healthcare workforce solutions, has been honored once again for its exceptional growth trajectory, being listed among the Midwest's fastest-growing companies. This prestigious recognition marks...

Continue Reading
Unlocking the Future: SEALSQ's MS6003 Secure Element Launch

Updated Category News Views 208

Revolutionizing Secure Authentication with MS6003 SEALSQ Corp (NASDAQ: LAES), a leader in semiconductor innovation, has recently announced a significant addition to its product portfolio: the MS6003 secure element chip. This state-of-the-art chip is equipped with a preloaded FIDO2 application, marking a pivotal step towards enhancing passwordless authentication in an era...

Continue Reading
Navigating Income with High-Dividend Utility Stocks Today

Updated Category News Views 114

Staying Afloat with Utility Stocks In challenging market conditions, many investors search for stability. This leads them to utility stocks, particularly those offering attractive dividend yields. Utilities often provide steady cash flows and dividends, making them appealing for income-seeking investors. Dividend Opportunities in Utilities Sector As the market shifts,...

Continue Reading